You are here

Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Research Site
Belo Horizonte, , Brazil
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and, Nosocomial Pneumonia (NP)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

ICF to be obtained (refer slides 26-30) Adult (≥18 years) patients Patients with a
diagnosis of at least one of the three conditions hospitalised during the period July 1,
2013 to June 30, 2014 Hospital acquired or healthcare associated cUTI Hospital acquired or
healthcare associated cIAI NP including VAP

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

The patient participated in a clinical trial during the patient selection period
(01-Jul-2013 to 30-Jun-2014) or during the follow-up period* For patients diagnosed with
cUTI: The patient has a diagnosis of hospital acquired or healthcare associated cUTI with
concomitant presence of Fungal UTI with colony count > 10^3/mL

NCT02364284
Pfizer
Completed
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With Complicated Urinary Tract Infection,Complicated Intra-abdominal Infection and Nosocomial Pneumonia Including Ventilator-associated Pneumonia.
Reporting patterns and results of initial antibiotic treatment in patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP) - RECOMMEND Study
This will be an observational, historical cohort study from medical chart review of adult hospitalized patients for each of the three conditions of interest (complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP)). For this study, the proposed patient selection period extends for 12 months, from July 1, 2013 to June 30, 2014. Patients selected during this period will be followed from diagnosis (i.e., diagnosis of cUTI, cIAI or NP) until symptom resolution, discharge or 30-days post discharge [based on data availability to assess readmission and outpatient visits], death while hospitalized, loss to follow-up or the end of study period if not yet discharged from index hospitalization [December 31, 2014]).
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Adult (?18 years) patients. Hospitalized patients with a diagnosis of at least one of the following three conditions during the period July 1, 2013 to June 30, 2014 should be included in this study.

Hospital acquired or healthcare associated cUTI Hospital acquired or healthcare associated cIAI NP including VAP

  • Urinary Tract Infection (cUTI)
  • Intra-abdominal Infection (cIAI) and
  • Nosocomial Pneumonia (NP)
Not Provided
  • Urinary Tract Infection (cUTI)
    Patients ?18 years with diagnosis of urinary tract infection.
  • Intra Abdominal Infection(cIAI)
    Patients ? 18 years with diagnosis of Intra Abdominal Infection
  • Nosocomial Pneumonia (NP)
    Patients ? 18 years with diagnosis of Hospital acquired pneumonia
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1322
February 2016
February 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

ICF to be obtained (refer slides 26-30) Adult (?18 years) patients Patients with a diagnosis of at least one of the three conditions hospitalised during the period July 1, 2013 to June 30, 2014 Hospital acquired or healthcare associated cUTI Hospital acquired or healthcare associated cIAI NP including VAP

Exclusion Criteria:

The patient participated in a clinical trial during the patient selection period (01-Jul-2013 to 30-Jun-2014) or during the follow-up period* For patients diagnosed with cUTI: The patient has a diagnosis of hospital acquired or healthcare associated cUTI with concomitant presence of Fungal UTI with colony count > 10^3/mL

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil,   France,   Greece,   Italy,   Russian Federation,   Spain
 
 
NCT02364284
D4280R00005
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Principal Investigator: Anne-Laure Fedou CHU de Limoges - Hôpital Dupuytren
Pfizer
September 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now